DBCO-PEG4-MMAF CAS:2360411-65-8 is a potent, advanced bioconjugation molecule consisting of three functional groups: DBCO (dibenzocyclooctyne), PEG4 (a 4-unit polyethylene glycol linker), and MMAF (monomethyl auristatin F), a potent cytotoxic agent. This unique combination enables efficient, targeted drug delivery through click chemistry reagents, enhancing the selectivity and efficacy of therapeutic agents.
In pharmaceutical research and development, DBCO-PEG4-MMAF has revolutionized targeted cancer therapies. By conjugating antibodies or other targeting ligands to the cytotoxic MMAF payload via the DBCO-PEG4 linker, this bioconjugate allows for selective delivery of the cytotoxic agent to cancer cells, reducing off-target effects and increasing the therapeutic index. This innovative approach has led to the development of novel antibody drug conjugate linkers (ADCs), advancing the field of precision medicine.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.